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Abstract
A modular, single chain polypeptide containing the low density 
lipoprotein receptor (LDLR) ligand Seq-1 and with blood-brain barrier 
(BBB) crossing activity, has been successfully modified by 
conventional genetic engineering to self-assemble into stable protein-
only nanoparticles of 30 nm. The nanoparticulate presentation 
dramatically enhances in vitro, LDLR-dependent cell penetrability of 
the protein compared to the parental monomeric version, but the 
assembled protein does not show any enhanced brain targeting upon 
systemic administration. While the presentation of protein drugs in 
form of nanoparticles is in general advantageous regarding correct 
biodistribution, this principle might not apply to brain targeting that is
hampered by particular bio-physical barriers. Irrespective of this fact, 
that is highly relevant to the nanomedicine of central nervous system,
engineering the cationic character of defined protein stretches is 
revealed here as a promising and generic approach to promote the 
controlled oligomerization of biologically active protein species as still 
functional, regular nanoparticles.
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Introduction
The design and biofabrication of nanoscale materials that mimic viral 
properties (such as self-assembling, cell surface receptor binding, 
internalization and proper intracellular trafficking) is highly promising 
for targeted drug delivery and gene therapy 1. Proteins are among the
most convenient materials for the generation of functional building 
blocks in nanoparticle construction 2-5. This is not only linked to 
protein functionalities but also to the fact that their spatial 
conformation, potential for cross-interactions and supramolecular 
organization can be designed and adjusted by simple genetic 
engineering. In addition, cost-effective biofabrication of proteins for 
therapeutic applications has been fully demonstrated in Bio-Pharma, 
and the emergence of novel cell factories and the implementation of 
genetic and systems approaches expand the opportunities for the 
biosynthesis of difficult proteins 6-8. Then, while protein production and
downstream are technically solved issues, the bases for a rational 
engineering of protein-protein cross molecular interactions remain to 
be fully established. 
Some architectonic principles have been proposed for the 
construction of peptide-based nanofibers and nanoparticles 4, 
exploiting the amphiphilic character of chemically modified short 
peptides 9 or the self-assembling properties of the β-sheet-rich 
amyloidal protein domains 10. Regarding long-lengthen proteins 
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suitable for biological production, the engineering of natural 
oligomerization domains into modular polypeptides has allowed the 
construction of protein nanoparticles based on hybrid fusion proteins 
acting as building blocks 11. Of course, the production of structural 
viral proteins renders, in some cases, complex structures known as 
virus like particles (VLPs) that architectonically mimic the natural viral
capsid versions. While largely proved to be excellent immunogens, 
the usability of VLPs and other nanostructured materials as vehicles 
for drug and nucleic acid delivery is rather narrow 12. This is because 
the limited versatility in the design of nanoscale physical properties 
and biological functions of the resulting nanoparticles, and on the 
other side, by the still partial comprehension of the mechanics of the 
cross-molecular interactions that govern the formation of stable 
supramolecular complexes. 
Recently, we have proposed a nanoscale architectonic principle that 
permits the generation of protein nanoparticles in which structurally 
unrelated protein species can act as building blocks 13. When tagged 
with a cationic amino terminal peptide and a polyhistidine tail at the 
carboxy terminus, these scaffold proteins (eg. GFP, IRFP, p53 and Hsp 
70), cross-interact by electrostatic interactions and form toroid 
structures stabilized by a complex set of alternative forces, including 
van der Wals and hydrogen bond interactions 14. These nanoscale 
materials, of regulatable size, allow the intracellular delivery of 
functional proteins to specific target cells and tissues upon systemic 
administration 14-16. In form of nanoparticles and when conveniently 
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empowered by tumor homing peptides, these proteins correctly 
biodistribute and accumulate, for instance, in CXCR4+ cancer stem 
cells in colorectal cancer models 14. However, recent indirect data 
suggested that the presentation of proteins as nanoparticulate 
entities might not favour protein delivery to brain 17. This might be 
indicative of different principles governing the biodistribution of 
protein nanoparticles depending on if they display tumor- or BBB-
homing peptides. To assess BBB-crossing and brain targeting 
properties of monomeric and nanoparticle versions of the same 
targeting peptide we have engineered for the first time, pre-existing 
BBB-homing polypeptides into building blocks that self-assemble as 
equivalent protein nanoparticles. Then, apart from determining the in 
vitro cellular penetrability, the biodistribution of both disassembled 
and assembled versions has been examined in vivo upon intravenous 
administration into healthy mice. Unexpectedly, while the cellular 
penetrability of protein nanoparticles is enhanced in vitro when 
compared to single molecular species, this is not accompanied by an 
enhanced ability of the protein to reach the brain. In addition to the 
protein engineering principles successfully tested here, the presented 
results indicate particular restrictions in nanoparticle performance in 
brain targeting, what should prompt the careful reconsideration of 
nanotechnological approaches to neurotropic vehicles for therapies 
and imaging.  
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Materials and methods
Protein design and gene cloning. Angiopep-2 
(TFFYGGSRGKRNNFKTEEY) 18 and Seq-1 (KYLAYPDSVHIW) 19, are 
peptides with known BBB-crossing activities, that have been 
previously used to construct brain-targeted GFP fusions. Derivatives 
of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 containing additional 
cationic amino acids (Table 1) were designed in house and obtained 
from Genscript (Piscataway, USA). The synthetic genes (Seq-1-7-GFP-
H6, Seq-1-8-GFP-H6, Angiopep-2-7-GFP-H6 and Angiopep-2-8-GFP-H6) 
were then inserted into the prokaryotic expression commercial pET-
22b vector (#69744-3, Novagen, USA) using NdeI/HindIII restriction 
sites. Escherichia coli BL21 (DE3) cells were transformed with 
recombinant pET22b plasmids by heat shock (45 sec, 42ºC) to allow 
protein production. 
Protein production and purification. Bacterial cells carrying the 
appropriate plasmid vector were cultured in 2L shaker flasks with 500 
ml of LB (Luria-Bertani, Conda Cat. 1551.00) medium containing 100 
μg/ml ampicillin, at 37 ºC until the OD550 reached 0.5-0.7. 
Recombinant gene expression was induced with 0.1 mM isopropyl-β-d-
thiogalactopyronaside (IPTG) and then, bacterial cells were kept 
growing overnight at 20 °C. Bacterial cells were then harvested by 
centrifugation at 5,000 g for 15 min at 4 °C and resuspended in Wash 
buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM imidazol, pH 8.0) PBS 
(phosphate buffered saline: 140 mM NaCl, 2.7 mM KCl, 10 mM 
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Na2HPO4, 1.8 mM KH2PO4) in the presence of EDTA-free protease 
inhibitor (Complete EDTA-Free; Roche). Cells were then disrupted in a 
French Press (Thermo FA-078A) and centrifuged for 45 min (15,000 g 
at 4ºC). All proteins were purified by His-tag affinity chromatography 
using HiTrap Chelating HP 1 ml columns (GE healthcare) by ÄKTA 
purifier FPLC (GE healthcare). After filtering the soluble fraction, 
samples were loaded onto the column and washed with 10 column 
volumes of Wash buffer. Bound proteins were eluted with Elution 
buffer (20 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 8.0) in a 
linear gradient. Purified fractions were collected and quantified by 
Bradford’s assay and analyzed by SDS-PAGE and MALDI-TOF. The 
medium-scale production of recombinant proteins was partially 
performed by the ICTS “NANBIOSIS”, more specifically by the Protein 
Production Platform of CIBER in Bioengineering, Biomaterials & 
Nanomedicne (CIBER-BBN)/ IBB, at the UAB (SepBioEs, 
http://www.ciber-bbn.es/es/programas/89-plataforma-de-produccion-
de-proteinas-ppp).
Microdialysis. Drops of purified proteins (20 µl) were deposited on 
VsWp02500 Millipore membrane filters floating on 20 ml of different 
buffers: Carbonate buffer (166 mM NaHCO3, pH 7.5), Carbonate + 
dextrose 5% (166 mM NaHCO3 pH 7.5 + 5 % dextrose), Carbonate + 
salt (166 mM NaHCO3 pH 7.5 + 200 mM NaCl) and HBS buffer 10x 
(HEPES-buffered saline pH 5.8; 50 mM KCl, 1.37 M NaCl, 8.5 mM 
Na2HPO4, 21 mM HEPES).
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Dialyzed drops were collected and centrifuged, and the soluble 
fractions were quantified to determine the extent of aggregation for 
each protein in different buffers. For further storage, proteins were 
finally dialyzed against their own most convenient buffer regarding 
protein stability (Seq-1-7-GFP-H6 and Seq-1-8-GFP-H6 against 
Carbonate buffer and Angiopep-2-7-GFP-H6 and Angiopep-2-8-GFP-H6
against Carbonate + 200 mM NaCl buffer) and stored at -80 C after 
0.22 pore membrane filtration. 
Fluorescence determination and dynamic light scattering (DLS). 
Volume size distribution of nanoparticles and monomeric GFP protein 
fusions was determined by DLS at 633 nm (Zetasizer Nano ZS, 
Malvern Instruments Limited, Malvern, UK). Fluorescence was 
determined in a Cary Eclipse fluorescence spectrophotometer (Varian 
Inc, Palo Alto, CA) at 510 nm using an excitation wavelength of 450 
nm.
For DLS analyses, proteins (stored at -80 C) were thawed and 
incubated on ice until use. 50 l of each sample were used in the 
corresponding stock concentration: Seq-1-7-GFP-H6: 2.67 mg/ml; Seq-
1-8-GFP-H6: 2.2 mg/ml ; Angiopep-2-7-GFP-H6: 3.93 mg/ml and 
Angiopep-2-8-GFP-H6: 2.58 mg/ml. For fluorescence determination, 
protein samples were diluted in the corresponding storage buffer to 
0.5 mg/ml, in a final volume of 100 l. The shown data refers to the 
volume peak of the materials (the mode). For some experiments, 
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protein samples were diluted to 1.5mg/ml in reconstituted human 
plasma (Sigma-Aldrich, Ref: S225-5 ml), and further incubated under 
agitation at 37 ºC.
Electron microscopy (TEM and FESEM). For transmission electron 
microscopy (TEM) two sets of purified proteins were diluted to 0.2-0.5 
mg/ml, deposited onto carbon-coated copper grids (300 mesh) and 
one of them contrasted by uranyl acetate and air-dried and the other 
one shadowed with 1 nm a platinum-carbon layer respectively. 
Samples were observed in a Jeol 1400 transmission electron 
microscope operating at 80kV and equipped with a CCD Gatan 
Erlangshen ES1000W camera. For field emission scanning electron 
microscopy (FESEM), microdrops of purified proteins diluted as for 
TEM were deposited onto a silicon wafer surface, air-dried and 
immediately observed in a Zeiss Merlin field emission scanning 
electron microscope operating at 1 kV and equipped with a high 
resolution in-lens secondary electron detector. 
Cell culture and flow cytometry. LDLR+ HeLa cells (ATCC-CCL-2) were 
used for the in vitro experiments. The cell line was cultured in Eagle's 
Minimum Essential Medium (Gibco, Rockville, MD) supplemented with 
10 % fetal calf serum (Gibco), and incubated at 37°C and 5 % CO2 in a
humidified atmosphere. Meanwhile bEnd.3 cell line was maintained in 
Dulbecco's Modified Eagle's Medium (DMEM: Gibco® GlutaMAX™) 
supplemented with 10 % fetal calf serum (Gibco), and incubated at 
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37°C and 10 % CO2 in a humidified atmosphere. Nanoparticles and 
proteins were added at different concentrations (ranging from 2 to 0.1
mM) to the cell culture in the presence of Optipro medium (Gibco) 24 
h before flow cytometry. Cell samples were analyzed on a FACSCanto 
system (Becton Dickinson) using a 15 W air-cooled argon-ion laser at 
488 nm excitation. GFP fluorescence emission was measured with a 
detector D (530/30 nm band pass filter) after treatment with 1 mg/mL
trypsin (Gibco) for 15 min. For time course analysis, nanoparticles 
were added at 2 mM final to the cell culture in the presence of Optipro
medium (Gibco) 24, 6, 4, 2 and 1 h, and 30 and 15 min before flow 
cytometry. Cell samples were analyzed after harsh treatment with 1 
mg/mL trypsin (Gibco) for 15 min to remove surface attached 
fluorescent protein 20.
Confocal microscopy. HeLa cells were grown on Mat-Teck culture 
dishes (Mat Teck Corporation, Ashland, MA). The nuclei were labeled 
with 10 μg/mL Hoechst 33342 (Molecular Probes, Eugene, OR) and the
plasma membranes with 5 μg/mL CellMaskTM Deep Red (Molecular 
Probes) in darkness for 10 min. Cells were washed in phosphate-
buffered saline (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) 
and proteins were added 20–24 h before staining at 2 mM. Live cells 
were recorded by TCS-SP5 confocal laser scanning microscopy (Leica 
Microsystems, Heidelberg, Germany) using a Plan Apo 63 ×/1.4 (oil 
HC × PL APO lambda blue) objective. To determine the location of 
particles inside the cell, stacks of 10–20 sections were collected at 0.5
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μm Z-intervals with a pinhole setting of 1 Airy unit. The 3-D 
reconstruction was performed using Imaris software (Bitplane, Zürich, 
Switzerland). 
Protein stability in human plasma. The stability of proteins was 
analyzed by measuring fluorescence emission after incubation in 
human plasma. Proteins were diluted, in triplicate, in human plasma 
(0.115 μg/μL final concentration). Human plasma was obtained from a
healthy donor in the Hospital de Sant Pau  complying with the 
regulation established by the Clinical Ethics Committee of the 
Institution.  
Immediately after dilution, samples were harvested (time 0) and their 
respective fluorescence was taken as the initial reference value (100 
%). Proteins were further incubated (at 37 ºC, with agitation), and 
samples were taken, at different time points, up to 24 h. Protein 
functional stability during incubations was analyzed by fluorescence 
determination at 510 nm in a Cary Eclipse fluorescence 
spectrophotometer (Variant, Inc., Palo Alto, CA) using an excitation 
wavelength of 450 nm.
Biodistribution. Female athymic nu/nu mice (Charles River, L´Abresle, 
France) between 4 to 6 weeks of age were housed in individually-
ventilated cages on a 12-h light-dark cycle at 21-23 ºC and 40-60 % 
humidity. Mice were allowed free-access to an irradiated diet and 
sterilized water. The experimental animals received a single 
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intravenous bolus of 500 μg of Seq-1-derived protein nanoparticles (or
the equivalent unassembled proteins) in 166 mM carbonate buffer pH 
7.5. Control animals received a single bolus of empty buffer. At 30 min
and 2 h post-administration, we sacrificed the mice and measured ex 
vivo the amount of nanoparticles in each relevant organs from the 
experimental and control mice, by quantifying the emitted 
fluorescence. Entire hemisected organs (brain, kidney, liver, lung, 
heart) were placed in separate wells to detect the emitted signal 
using IVIS® Spectrum equipment (PerkinElmer Inc, Waltham, MA). 
The fluorescence signal was first digitalized, displayed as a 
pseudocolor overlay, and finally expressed as radiant efficiency. 
Differences in signals were analyzed by a non-parametric Man-
Whitney test. The study was approved by the institutional ethical 
committee and all procedures were in accordance with institutional 
guidelines. Humane care of the animals was always applied 
accordingly.
Results
Protein design, production and characterization. Angiopep-2-GFP-H6 
and Seq-1-GFP-H6 are modular proteins displaying low density 
lipoprotein receptor (LDLR) ligands at their amino termini (Angiopep-2
and Seq-1 respectively) (Table 1), that reach the brain upon systemic 
administration 17. Both Angiopep-2 and Seq-1 are well known BBB-
crossing peptides proven useful as brain-homing agents in drug 
delivery 18, 19. At difference of the related construct ApoB-GFP-H6 that 
13
form nanoparticles of 18 nm in diameter 17, these proteins do not 
show any self-assembling activity and remain monomeric. In an 
attempt to upgrade Angiopep-2-GFP-H6 and Seq-1-GFP-H6 
polypeptides up to self-assembling building blocks for nanoparticle 
construction, arginine- and lysine- containing stretches were designed
for their introduction in both proteins, between the ligand and the 
linker to the scaffold GFP (Table 1, segments in bold). Two versions of 
the supplementary cationic peptides were constructed to offer a total 
of 7 or 8 positively charged residues in the amino terminal region. 
According to previous numerical modelling 15, these numbers of 
cationic residues, if properly placed, should enable the proteins to 
self-organize as nanoparticles of around 30 nm. This numerical model 
identifies a relationship between the number of cationic residues at 
the amino terminus of the building blocks, and the size of the 
engendered particles, and it resulted from empirical data recruited 
from a set of different modular proteins. So far, the model had been 
never tested as a rational tool for the engineering of protein self-
assembling.
The four new versions of Angiopep-2-GFP-H6 and Seq-1-GFP-H6 were 
produced in bacteria resulting in full-length soluble species with 
predicted molecular masses (Table 1) and retaining the GFP 
fluorescence emission. The  reduction of the fluorescence emission 
capacity, that is clearly significant (p<0.01) in the case of  Seq-1-
derivatives, is indicative of moderate conformational changes in the 
protein that while keeping the barrel organization might affect the 
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conformation of the chromophore. While the parental versions sized 
around 5-6 nm by DLS analysis, compatible with monomeric or 
dimeric GFP forms, the protein Seq-1-8-GFP-H6 was observed as 
nanoparticulate entities of around 30 nm, significantly different in size
from unassembled monomers (Figure 1 A) and indicating a 
supramolecular organization of the individual polypeptide chains. The 
formed nanoparticles occurred and were stable in different buffers 
against which the protein was dialyzed (Figure 1 B), proving the 
structural robustness of the constructs under different salt contents 
and ionic strengths. In agreement, and fully supporting the taken 
approach to the engineering of building blocks, TEM and FESEM 
examinations confirmed the occurrence of these proteins as 
nanoparticles of regular size and morphology (Figure 1 C-E). 
Interestingly, high magnification TEM images of Seq-1-8-GFP-H6 
showed an architectonic scheme (a circular electrodensity pattern) 
compatible with a toroid organization, similar to that recently shown 
for the related protein T22-GFP-H6 14. This particular geometry was 
fully confirmed by high resolution FESEM analysis of the same 
samples (Figure 1 E). As expected, no nanoparticles but some 
unspecific aggregates with different shape and size were observed 
when examining Seq-1-7-GFP-H6 samples (Figure 1 C). As shown in 
Figure 1A, none of the Angiopep-2-GFP-H6-derived proteins formed 
nanoparticles. 
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In vitro analysis of cellular internalization.  At this stage, we were 
interested in the biological characterization of Seq-1-8-GFP-H6 
nanoparticles regarding their ability to penetrate target cells, and 
especially in comparison with the closely related, unassembled 
protein Seq-1-7-GFP-H6 that only differs by a single missing arginine 
residue (Table 1). Before that, we determined that the fluorescence of 
Seq-1-8-GFP-H6 nanoparticles and of the whole set of unassembled 
proteins remained stable in human plasma in vitro at 37 ºC for at 
least 24 h (Figure 2 A). The protein stability in presence of a complex 
organic medium prompted us to use fluorescence as a marker to 
monitor cell penetrability by flow cytometry, in LDRL-expressing HeLa 
cells. As observed (Figure 2 B), Seq-1-8-GFP-H6 penetrated HeLa cells 
much more efficiently than the closely related construct Seq-1-7-GFP-
H6 and that the monomeric versions of Angiopep-2-displaying 
proteins. Also, the levels of Seq-1-8-GFP-H6 internalization were 
comparable to those observed for the related R9-GFP-H6 
nanoparticles used here as control, that are empowered by a potent 
Tat-inspired cell penetrating peptide (nine arginines, R9). R9 promotes
receptor-independent fast cell penetrability and nuclear migration in 
HeLa and other cell types 21-23. The similar uptake of Seq-1-8-GFP-H6 
was indicative of an enhanced penetrability of the Seq-1 ligand when 
organized in a nanoparticulate form. Confocal images of HeLa cells 
exposed to Seq-1-derived proteins confirmed the poor penetrability of
Seq-1-7-GFP-H6 (Figure 3 A) and the intracellular location of Seq-1-8-
GFP-H6 (Figure 3 B), discarding mere external association to the cell 
16
membrane. Also, 3D reconstructions of exposed cultures resulted in 
images compatible with the expected endosomal route for Seq-1-8-
GFP-H6 uptake, based on the merging of red (membranes) and green 
(nanoparticles) signals (Figure 3 C).
To evaluate if the enhanced cell internalization of Seq-1-8-GFP-H6 (in 
comparison to Seq-1-7-GFP-H6) would impact on the BBB-crossing 
abilities of Seq-1 we first tested both proteins in a CaCo-2 cell 
permeability system recognized as a relevant in vitro model of the 
BBB 24. In this test, Seq-1-8-GFP-H6 showed transcytic properties 
clearly superior to those exhibited by Seq-1-7-GFP-H6 (Table 2), again 
in the line of the higher cell penetrability of a nanoparticulate version 
of the homing peptide Seq-1.  
Biodistribution and BBB-crossing
When administered intravenously in healthy mice models with intact 
BBB, both Seq-1-7-GFP-H6 and Seq-1-8-GFP-H6 transiently 
accumulated in brain (Figure 4A), over the background values derived
from GFP-H6 administration (Figure 5 B). Despite being more efficient 
in cell penetration in vitro (Figure 2 and 3, and Table 2), the 
nanoparticulate version of Seq-1, namely Seq-1-8-GFP-H6, did not 
show any improvement of CNS targeting regarding the unassembled 
Seq-1-7-GFP-H6 form. On the other hand, any of these proteins were 
found in liver, heart and lung, but in kidney (Figure 5 A). The 
occurrence in kidney was not unforeseen in the cases of GFP-H6 and 
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the unassembled Seq-1-7-GFP-H6, which are cleared by renal 
glomeruli. However, Seq-1-8-GFP-H6 nanoparticles would be expected
to escape from renal filtration and occur only in target organs, as 
observed in the case of similar constructs functionalized with tumor-
homing peptides 15. This could be indicative of a partial disassembling
of Seq-1-8-GFP-H6 nanoparticles in vivo, due to the high ionic 
strength and the presence of a complex spectrum of interacting 
human proteins, and a consequent reduction of the Seq-1-8-GFP-H6 
material size from 30 nm (nanoparticles) to less than 8 nm 
(unassembled building blocks). While this does not occur in the case 
of the structurally related, more cationic T22-IRFP-H6 nanoparticle 14, 
that is fully stable during circulation in blood, it would be not 
unexpected in the case of the less cationic Seq-1-8-GFP-H6, since the 
absence of one single lysine (in Seq-1-7-GFP-H6) precludes self-
assembling. To check this possibility, we explored in vitro the 
nanoparticle stability in presence of human sera, at 37 ºC, to mimic 
post injection conditions. As observed (Figure 5B), Seq-1-8-GFP-H6 
nanoparticles loosed stability with incubation time, showing a 
moderate reduction of size at 2 h and resulting essentially 
disassembled at 5 h. Partial in vivo disassembly at 2 h would, at least 
to some extent, account for the presence of the material in kidney. 
However, while the amount of monomeric GFP-H6 and Seq-1-7-GFP-
H6 dramatically decreased from 30 min to 2 h post administration, as 
expected for materials ≤ ~8 nm in size, Seq-1-8-GFP-H6 nanoparticles 
remained in kidney for longer times (Figure 5C). This fact suggested 
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issues additional to size-dependent filtration as contributors in 
regulating its occurrence in kidney. 
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Discussion
By using empirical information from of a set of closely related proteins
with and without self-assembling properties 25, we have designed and 
constructed protein-only nanoparticles containing the Seq-1 BBB-
crossing peptide (Figure 1). This has been done by the addition of 
several cationic peptides at the amino terminus of the modular 
protein Seq-1-GFP-H6 (Table 1), a polypeptide that exclusively 
remains in unassembled form (Figure 1). A similar attempt to engineer
the self-assembling of Angiopep-2-GFP-H6 failed (Figure 1) probably 
because the more scattered distribution of cationic residues (Table 1). 
This would result in a less polar splitting of the electrostatic charges 
necessary for the assembling of building blocks 13-15. In fact, one 
additional cationic lysine residue in Seq-1-8-GFP-H6 compared to Seq-
1-7-GFP-H6 was sufficient to efficiently triggering self-assembling 
(Table 1, Figure 1). Seq-1-8-GFP-H6 nanoparticles exhibited the 
expected size of 30 nm (Figure 1 A), a toroid organization (Figure 1 C, 
E) and a higher cellular penetrability into LDLR+ HeLa cells when 
compared with the unassembled Seq-1-7-GFP-H6 version (Figure 2, 3).
In addition, the transcytic properties of Seq-1-8-GFP-H6, measured in 
a CaCo-2-based test 24, were clearly superior to those exhibited by the
unassembled form Seq-1-7-GFP-H6 (Table 2). Since the mere addition 
of cationic peptides to pre-existing protein nanoparticles did not alter 
cell penetrability per se 26, the formation of nanoparticles rather that 
the single amino acid addition in Seq-1-8-GFP-H6 would be 
responsible for enhanced cell penetrability. A higher penetrability of 
20
protein nanoparticles compared with individual building blocks is in 
agreement with previous results obtained in our laboratory 27 and it is 
probably related with the multivalent presentation of the cell ligands 
(Seq-1, in the present case) on the surface of nanoparticles that 
favours endosomal entrapment 28. The endosomal route of Seq-1-8-
GFP-H6 nanoparticle uptake is confirmed by the strong merging 
signals (yellowish spots, merging green and red) observed in in vivo 
internalization assays (Figure 3 B, C). Of course, the mere 
enlargement of the material size associated to oligomerization might 
also promote endocytosis, as size of nanoparticles generically 
determines the nature of cell responses upon exposure, including 
signalling and endocytosis 29. Among nanoparticles between 2 and 
100 nm, those sizing between 40 and 50 nm show the strongest 
effect on cell responses, representing a size range compatible with 
what has been generically found as optimal for cell internalization in 
other independent studies 30-32.
Despite the dramatic improvement of cell penetrability and 
transcytosis exhibited by the nanoparticulate versus free form of Seq-
1 homing peptide, the accumulation in brain of Seq-1-7-GFP-H6 and 
Seq-1-8-GFP-H6 were similar and indistinguishable (Figure 4). This fact
indicates that the multivalent presentation of the Seq-1 LDLR ligand in
organized nanoparticles has no relevant impact on BBB permeability 
in healthy animals. This is in agreement with recent data 17 regarding 
the poor brain penetrability of nanoparticles empowered with the 
BBB-crossing peptide ApoB 33, and it could be due to different 
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transcytosis activities between epithelial kidney cells and brain 
endothelial cells, as previously described for a different receptor 34.
On the other hand, both Seq-1-7-GFP-H6 and Seq-1-8-GFP-H6 were 
found in kidney (but not in other organs), as in the case of the 
parental protein GFP-H6 (Figure 5A). This could be interpreted by 
assuming an imperfect stability of Seq-1-8-GFP-H6 nanoparticles that 
might (at least partially) disassemble once in the blood stream. In 
fact,  in vivo disassembling of protein nanoparticles is not totally 
unexpected since it has been already described that nab-paclitaxel 
nanoparticles (known as Abraxane and sizing 130 nm), that are fully 
stable in physiological buffers and in saline solution, quickly 
separated into individual albumin-paclitaxel complexes once injected 
into the blood stream 35. In this context, Seq-1-8-GFP-H6, that 
exhibited the same size (30 nm) in human sera than in buffer (Figure 
1), appeared only as partially stable in sera under prolonged 
incubation (Figure 5B), as a reduction of particle size was observed 
after 2 h of incubation and a significant occurrence of monomers at 5 
h, a later time point than those considered for biodistribution analyses
(30 min and 2 h) . On the other hand, the presence of heterologous 
proteins in human sera, would also promote, at east at some extent, 
structural or functional instability of the material by the presence of 
the corona 36. However, the dynamic analyses of the renal occurrence 
of the proteins analysed here (Figure 5C) shows clear and significant 
differences when comparing the monomeric versions (GFP-H6 and 
Seq-1-7-GFP-H6) and the multimeric form Seq-1-8-GFP-H6. This last 
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protein remains for longer time in kidney, suggesting that in addition 
to a potential size-dependent renal filtration of part of the material, its
occurrence in the tissue might rely on a specific interaction between 
Seq-1 and tissue specific receptors such as megalin. Megalin, a cell 
surface receptor of the LDLR family found in renal cell types,  
participates in lipid metabolism in the kidney 37, showing a high 
capacity for taking up lipid-binding proteins into the renal proximal 
tubule epithelial cells where it is highly expressed 38. It is known that 
protein uptake by the proximal tubules is the main process ensuring 
the lack of proteins in urine. Moreover, since it occurs distally to 
glomerular filtration, only proteins of a size lower than the filtration 
cut-off (8 nm) can be taken up 39.  Despite this, some receptor 
expression might occur in the endothelia of the glomerulus, 
accounting for a certain level of specific binding of nanomaterials over
8 nm. Although this hypothesis would obviously need further solving, 
the abundance of LDLR in kidney might discourage the use of LDLR 
ligands in nanoparticles targeted to brain, especially if they occur in 
sizes close to the renal cut-off. 
In this study, we have engineered the brain-targeted polypeptide Seq-
1-GFP-H6 to self-assemble into regular, protein-only nanoparticles 
formed by multiple copies of the resulting protein Seq-1-8-GFP-H6. 
Seq-1-8-GFP-H6 differs from the parental protein by 7 cationic 
residues that were inserted into a permissive region of the protein, 
between the Seq-1 peptide and the core GFP (Table 1). The resulting 
fluorescent nanoparticles show a dramatic improvement of cell 
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penetrability and transcytic activities in vitro regarding monomeric 
versions, but contrarily, the brain targeting properties did not result 
improved by the multimerization (Figure 4). The engineering principle 
developed here should permit the construction of protein-based 
nanoparticles by the precise sequence manipulation of pre-existing 
proteins that increase, in a controlled way, the cationic load of the 
amino terminal regions. Also, the progressive developments in 
systems and genetic approaches to recombinant protein production 40 
increasingly facilitate protein engineering, biofabrication in cell 
factories 41 and downstream 41,42. In the current bubbling context of 
novel protein drugs of interest in cancer therapies and for other 
conditions 44, formulating such therapeutic proteins as nanoparticles 
would offer an interesting engineering tool with a broad applicability 
in nanomedicine, as the multivalent presentation of homing agents in 
those materials, either natural or added, is expected to dramatically 
enhance cell uptake.
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Legends
Figure 1. Formation and structure of Seq-1-8-GFP-H6 nanoparticles.
A) Size of Angiopep-2- and Seq-1-derived proteins measured by DLS
in  Carbonate  buffer  +  200  mM  NaCl  and  Carbonate  buffer
respectively. The size of Seq-1-8-GFP-H6 nanoparticles is significantly
different  from  the  size  of  both  Seq-1-7-GFP-H6  monomers  and
Angiopep-2  derivatives  (p<0.01). B)  Stability  of  Seq-1-8-GFP-H6
nanoparticle  in  different  physiological  buffers.  C-D)  Ultrastructural
morphology  of  Seq-1-8-GFP-H6  nanoparticles  at  three  different
magnifications compared to the unassembled related protein Seq-1-7-
GFP-H6 using shadowing of Pt/C (C) and negative staining (D) both
with TEM, and deposition in silicon wafers for FESEM (E). Bar size is 50
nm.
Figure 2. Biological characterization of  modular proteins.  A)  Time-
dependent emission stability of protein constructs in human plasma.
B) Penetrability of the different protein constructs in cultured  LDLR+
HeLa  cells,  determined  by  flow  cytometry  upon  harsh  trypsin
treatment 20. Crude fluorescence values were corrected by the specific
emission of each protein for comparative purposes. Data refers to 24
h post exposure. 
Figure 3. Internalization of protein constructs. Localization of protein 
Seq-1-7-GFP-H6 (A) and of Seq-1-8-GFP-H6 nanoparticles (B) upon 24 
h of exposure to cultured HeLa cells, observed by fine confocal 
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sections at two magnifications (top and bottom). Nuclear DNA is 
stained in blue, the membranous system in red, while nanoparticles 
and unassembled proteins are seen in green since they are naturally 
fluorescent. C) Endosomal localization of Seq-1-8-GFP-H6 
nanoparticles as observed by the yellowish merging of green and red 
signals in 3D confocal reconstructions.
Figure 4.  Brain targeting of Seq-1-derived proteins upon systemic
administration at 500 µg dose. A) BBB-crossing registered ex vivo by
GFP fluorescence determination in mouse whole brain (W) and brain
sections (S) 30 min and 2 h after intravenous administration. Crude
fluorescence values were corrected by the specific emission of each
protein for comparative purposes. B) GFP fluorescence values in brain
sections. Data are normalized by the specific fluorescence. The scale
and fluorescence signal  values are expressed as Radiant efficiency
[p/sec/cm2/sr] µW/cm2. Those groups showing significant differences
with the rest of the groups are labelled with symbols (*, # p<0.05).
Figure  5.  Renal  clearance  and  biodistribution  of  Seq-1-derived
proteins  upon  systemic  administration  of  500  µg. A) Ex  vivo
determination  of  GFP  fluorescence  signal  in  kidneys  and  other
relevant  organs  such  livers,  hearts  and  lungs,  at  the  same  post-
injection  times.  Crude  fluorescence  values  were  corrected  by  the
specific emission of each protein for comparative purposes. B) Size
variation  of  Seq-1-8-GFP-H6  materials  during  incubation  in  human
plasma.  C) GFP  fluorescence  values  in  kidney  sections.  Data  are
27
normalized by the specific fluorescence. The scales and fluorescence
signal  measures are expressed as Radiant efficiency [p/sec/cm2/sr]
µW/cm2. Those groups showing significant differences with the rest of
the groups are labelled with symbols (# p<0.05).
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